News
Europe's Cannabis Potency Problem Is Becoming a Public Health Question
A research paper published in Frontiers examining the mental health consequences of contemporary cannabis use across Europe has brought renewed attention to a question that Malta's regulators and harm reduction community cannot afford to ignore: as cannabis products become stronger, are public health frameworks keeping pace?
The study focuses on three intersecting variables — rising product potency, evolving patterns of use, and the varying capacity of health systems across Europe to respond. Its conclusions are sobering. High-potency cannabis, particularly products with elevated tetrahydrocannabinol (THC) concentrations, is associated with a measurably higher risk of adverse mental health outcomes, including psychosis-related presentations, anxiety disorders, and cannabis use disorder. The research also notes that daily or near-daily use compounds these risks significantly.
Potency Is the Central Variable
What distinguishes this body of research from earlier cannabis-and-mental-health literature is its attention to potency as an independent risk factor, separate from frequency of use. European cannabis markets have shifted dramatically over the past two decades. Average THC concentrations in herbal cannabis and resin products seized across the European Union have risen consistently, with some product types now regularly testing above 20% THC — a far cry from the street cannabis of the 1990s.
The Frontiers paper argues that health systems, mental health services, and public education campaigns have not adapted quickly enough to this new reality. Clinicians trained to assess cannabis use disorder using older criteria may be underestimating risk in patients presenting with high-potency use habits.
What This Means for Malta's CHRA Model
Malta occupies a distinctive position in the European cannabis landscape. Under the Responsible Use of Cannabis Act, Cannabis Harm Reduction Associations — known as CHRAs — are licensed to cultivate and distribute cannabis to adult members on a not-for-profit basis. The Authority on the Responsible Use of Cannabis (ARUC) oversees licensing, compliance, and the broader regulatory environment.
Central to the Maltese model, at least in principle, is harm reduction. CHRAs are not dispensaries in the commercial sense; they are associations with a statutory obligation to provide members with information about responsible use. The European research on potency and mental health therefore lands directly in their court.
At least one CHRA operating in the south of Malta has reportedly begun incorporating more structured consumption guidance into its member onboarding process, including information on THC concentration, consumption method, and indicators of problematic use. Whether such practices are consistent across the sector, however, is less clear.
ARUC's Role in Setting the Standard
The Frontiers research underscores the importance of product monitoring and labelling as public health tools. In jurisdictions where cannabis potency data is collected systematically, health authorities can respond more precisely — targeting interventions at high-risk user groups or flagging products that exceed thresholds associated with elevated harm.
ARUC has the regulatory mandate to set standards for cannabis cultivation and distribution within the CHRA system, including rules around THC limits for products made available to members. Whether current thresholds and labelling requirements reflect the latest European evidence on potency-related harm is a question worth putting to the authority directly.
For its part, the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) has long advocated for potency monitoring as a baseline public health measure. Malta, as an EU member state, is a contributor to EMCDDA reporting frameworks — a connection that should, in theory, ensure local policy remains anchored to the best available European evidence.
A Gap Between Evidence and Practice
The broader message from the Frontiers study is that legalisation or decriminalisation frameworks, however well-intentioned, do not automatically produce better health outcomes. The design details matter: what information reaches consumers, what potency limits apply, whether healthcare professionals are trained to recognise cannabis-related presentations, and whether harm reduction is genuinely embedded in how cannabis is distributed.
Malta's CHRA model was designed with many of these concerns in mind. The question, as European research continues to sharpen its picture of high-potency risk, is whether the implementation is rigorous enough to deliver on that promise — and whether ARUC has the resources and political backing to enforce standards that keep pace with the evidence.
That is a conversation the local cannabis community, healthcare professionals, and policymakers will need to have openly, and soon.
Sources
Frontiers — "Mental health consequences of contemporary cannabis use in Europe: potency, patterns of use, and health system context"
Featured image: Photo by Jess Loiterton on Pexels
Members Discussion